Over-activation of the receptor, causing excessive influx of Ca ++ can lead to excitotoxicity. The NMDA-Rs encompass three main subtypes (1, 2 and 3) with different modes of action. Magnesium sulphate (Mg) neuroprotective effect in preterm births is mediated in part via blocking of NMDA-Rs. We sought to determine the expression of preterm fetal brain NMDA-R subtypes and the response to inflammation and MG treatment. STUDY DESIGN: Pregnant rats at 16 and 18 days of gestation (48 rats; n¼6 per group) received injections of LPS (500 ug/kg i.p.) or saline at time 0. Dams were randomized to treatment with s.c. saline or Mg (270 mg/kg loading followed by 27 mg/kg q20 min) for 2 hours prior to and following LPS/saline injections. Rats were sacrificed 4 hours following LPS/ saline injection. Fetal brains were harvested and NMDA1-R, NMDA2-R and NMDA3-R protein levels and expression determined by western blot. RESULTS: Saline group: At e16 fetal brain NMDA-R subtypes 1, 2 and 3 protein levels were similar (0.11+0.01, 0.11+0.01, 0.10+ 0.01 u, corresponding to 34%, 34%, 32% respectively). At e18 all NMDA-R subtypes were comparable to their e16 levels (32%, 30%, 38%, respectively). Inflammation group: Following maternal inflammation at e16 and e18 all NMDA-Rs subtypes protein levels increased by approximately two-fold. Mg treatment to LPS dams significantly reduced all NMDA-R subtypes to levels similar to control at both e16 and e18. Interestingly, Mg administration to Controls group at e16 significantly decreased (p<0.05) NMDA1-R and NMDA2-R by 10-20%, with no effect on NMDA3-R. At e18, Mg administration to Controls had no effect on NMDA1-R and NMDA2-R, but significantly (p<0.05) decreased NMDA3-R protein levels by 30%. CONCLUSION: Mg neuroprotective effect in preterm birth may be mediated via modulation of the expression of NMDA-Rs thus decreasing Ca ++ induced excitotoxicity. However, Mg treatment may have NMDA-R subtype effects dependent upon gestational age that might interfere with the normal development of the synaptic plasticity.
OBJECTIVE: To assess long-term outcomes of children born after midtrimester preterm prelabor rupture of the membranes (PPROM between 16 and 24 weeks) and oligohydramnios, randomized to serial amnioinfusion or no intervention. STUDY DESIGN: This was a follow-up study of children born to women who participated in the PPROMEXIL-III trial (NTR3492). This trial compared amnioinfusion (n¼28) versus no intervention (n¼28). We invited parents for a neurodevelopmental test of their children up to 5 years of corrected age, and asked parents to complete questionnaires regarding behavior and respiratory problems. Mild neurodevelopmental delay (score 85,-1SD in one or more index scores), severe neurodevelopmental delay (defined as +2SD, -2SD or >97 th percentile) and respiratory problems were reported in relation to trial assignment and for all survivors. We also reported 'Healthy long-term survival' (survival after midtrimester PPROM without mild neurodevelopmental delay or respiratory problems) and used multiple imputation for missing data. RESULTS: There were 17/56 (30%) children who survived up to 5 years. In the amnioinfusion group 13 (46%) children died antepartum, and 5 (18%) died postpartum. In the expectant management group 15 (54%) died antepartum and 6 (21%) postpartum (relative risk (RR) for death at any time 0.86; 95% confidence interval (CI) 0.60-1.22). Follow-up data were obtained from 14/17 (82%) surviving children, of whom 10 mothers had received amnioinfusion and 4 no intervention. Analyses of these 14 children, disrespectful of trial assignment, showed that 10 children survived without a mild neurodevelopmental delay (-1SD) or severe delay (-2SD). Survival without respiratory problems occurred in 9 cases (Figure 1 ). Analysis after imputations showed that 'Healthy longterm survival' occurred in 5/28 (18%) in the amnioinfusion group and 5/28 (18%) in the no intervention group (RR 1.0; 95% CI 0.51-1.98) (Figure 2) . CONCLUSION: In women suffering midtrimester PPROM, 30% of the children survived until childhood. Surviving with normal development and no respiratory problems was comparable for both treatment groups. The power of our study was insufficient to identify any benefit from amnioinfusion. 
